-
-
表 1 国外癌痛爆发痛治疗常用的芬太尼剂型
表 2 阿片类药物相关异常行为的定义
-
[1] van den Beuken-Van EM, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years [J]. Ann Oncol, 2007, 18(9):1437-1449. doi: 10.1093/annonc/mdm056 [2] Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients[J]. J Pain Symptom Manage, 2013, 46(5):619-628. doi: 10.1016/j.jpainsymman.2012.12.009 [3] Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey [J]. Palliat Med, 2004, 18(3):177-183. http://cn.bing.com/academic/profile?id=1620836026c8ab26c64f01b40cdb3c30&encoded=0&v=paper_preview&mkt=zh-cn [4] Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics[J]. Pain, 1990, 41(3):273-281. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ027368529/ [5] Fallon M, Giusti R, Aielli F, et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines[J]. Ann Oncol, 2018, 29(S4): v166-v191. [6] Mercadante S, Marchetti P, Cuomo A, et al. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group[J]. Supportive Care in Cancer, 2016, 24(2):961-968. doi: 10.1007/s00520-015-2951-y [7] Davies AN, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the science committee of the association for palliative medicine of great Britain and Ireland[J]. Eur J Pain, 2009, 13(4):331-338. doi: 10.1016/j.ejpain.2008.06.014 [8] Zimmermann M, Richarz U. End-of-dose pain in chronic pain: does it vary with the use of different long-acting opioids[J]? Pain Pract, 2014, 14(8): 757-769. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM24373184 [9] Webber K, Davies AN, Zeppetella G, et al. Development and validation of the breakthrough pain assessment tool (BAT) in cancer patients[J]. J Pain Symptom Manage, 2014, 48(4):619-631. doi: 10.1016/j.jpainsymman.2013.10.026 [10] Daeninck P, Gagnon B, Gallagher R, et al. Canadian recommendations for the management of breakthrough cancer pain[J]. Current Oncol, 2016, 23(2):96-108. doi: 10.3747/co.23.2865 [11] Esparza-Miñana JM. Diagnosis and treatment of breakthrough pain[J]. Med Clin (Barc), 2018, 150(3):114-118. doi: 10.1016/j.medcli.2017.10.001 [12] Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care[J]. Cancer, 2002, 94(3):832-839. doi: 10.1002/(ISSN)1097-0142 [13] Wengstrom Y, Geerling J, Rustoen T. European oncology nursing society breakthrough cancer pain guidelines[J]. Eur J Oncol Nurs, 2014, 18(2): 127-131. doi: 10.1016/j.ejon.2013.11.009 [14] NCCN. Adult cancer pain[J]. NCCN Clin Pract Guide Oncol, 2013, (2):247- 270. http://d.old.wanfangdata.com.cn/Periodical/lczlxzz200901019 [15] Corli O, Roberto A. Pharmacological and clinical differences among transmucosal fentanyl formulations for the treatment of breakthrough cancer pain: a review article[J]. Minerva Anestesiol, 2014, 80(10):1123- 1134. http://cn.bing.com/academic/profile?id=445b4cecb3e799be6cf170838159e7d1&encoded=0&v=paper_preview&mkt=zh-cn [16] Noble-Gresty J. Recent and upcoming approaches in the management of cancer breakthrough pain[J]. Rev Pain, 2010, 4(2):2-7. doi: 10.1177/204946371000400202 [17] Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients[J]. J Natl Cancer Inst, 1998, 90(8): 611-616. doi: 10.1093/jnci/90.8.611 [18] Hagen NA, Fisher K, Victorino C, et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials[J]. J Palliat Med, 2007, 10(1):47-55. doi: 10.1089/jpm.2006.0151 [19] Mercadante S, Marchetti P, Cuomo A, et al. Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group[J]. Support Care Cancer, 2016, 24 (2):961-968. doi: 10.1007/s00520-015-2951-y [20] 王昆, 金毅.难治性癌痛专家共识(2017年版)[J].中国肿瘤临床, 2017, 44(16):787-793. http://html.rhhz.net/ZGZLLC/html/2017-16-1.htm [21] Olarte JM. Breakthrough cancer pain and rational drug use[J]. Support Care Cancer, 2017, 25(S1):11-17. doi: 10.1007/s00520-017-3636-5 -
下载:
点击查看大图
图(1) / 表(2)
计量
- 文章访问数: 389
- HTML全文浏览量: 33
- PDF下载量: 141
- 被引次数: 0
